X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ACTAVIS (US) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
ACTAVIS
Dec-14
DIVIS LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,22218,553-   
Low Rs78411,317-   
Sales per share (Unadj.) Rs153.13,340.9-  
Earnings per share (Unadj.) Rs39.9-416.9-  
Cash flow per share (Unadj.) Rs44.6306.5-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.87,246.3-  
Shares outstanding (eoy) m265.47265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.5 146.5%   
Avg P/E ratio x25.1-35.8 -70.1%  
P/CF ratio (eoy) x22.548.7 46.2%  
Price / Book Value ratio x5.02.1 241.1%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2663,971,215 6.7%   
No. of employees `0009.721.6 45.1%   
Total wages/salary Rs m4,6870-   
Avg. sales/employee Rs Th4,175.041,127.2 10.2%   
Avg. wages/employee Rs Th481.50-   
Avg. net profit/employee Rs Th1,089.3-5,132.2 -21.2%   
INCOME DATA
Net Sales Rs m40,643888,347 4.6%  
Other income Rs m749-2,217 -33.8%   
Total revenues Rs m41,392886,129 4.7%   
Gross profit Rs m14,460114,121 12.7%  
Depreciation Rs m1,233192,359 0.6%   
Interest Rs m2328,020 0.1%   
Profit before tax Rs m13,953-108,476 -12.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,957 0.0%   
Tax Rs m3,349-5,577 -60.1%   
Profit after tax Rs m10,604-110,856 -9.6%  
Gross profit margin %35.612.8 277.0%  
Effective tax rate %24.05.1 466.9%   
Net profit margin %26.1-12.5 -209.1%  
BALANCE SHEET DATA
Current assets Rs m40,105468,045 8.6%   
Current liabilities Rs m6,595341,342 1.9%   
Net working cap to sales %82.514.3 578.1%  
Current ratio x6.11.4 443.5%  
Inventory Days Days11958 204.3%  
Debtors Days Days8166 121.7%  
Net fixed assets Rs m19,995108,476 18.4%   
Share capital Rs m5310-   
"Free" reserves Rs m53,0430-   
Net worth Rs m53,5741,926,791 2.8%   
Long term debt Rs m01,009,676 0.0%   
Total assets Rs m61,5853,531,174 1.7%  
Interest coverage x618.4-2.9 -21,537.1%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.70.3 262.3%   
Return on assets %17.3-2.3 -735.6%  
Return on equity %19.8-5.8 -344.0%  
Return on capital %26.1-3.0 -866.4%  
Exports to sales %00-   
Imports to sales %25.20-   
Net fx Rs m24,9850-   
CASH FLOW
From Operations Rs m11,493152,546 7.5%  
From Investments Rs m-11,372-365,255 3.1%  
From Financial Activity Rs m-93205,220 -0.0%  
Net Cashflow Rs m28-7,488 -0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare DIVIS LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC PHARMA  GSK PHARMA  NOVARTIS  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 19, 2018 03:37 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - MERCK LTD COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS